David Elsley
Founder chez CARDIOL THERAPEUTICS INC.
Fortune : 2 M $ au 31/03/2024
Profil
David G.
Elsley is the founder.
He founded Vasogen, Inc. in 1990 and served as Director until 2009.
He also founded Cardiol Therapeutics, Inc. in 2017 and currently serves as President, Chief Executive Officer & Director.
Mr. Elsley holds an MBA from the University of Western Ontario and Richard Ivey School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 29/02/2024 | 1 154 500 ( 1,77% ) | 2 M $ | 31/03/2024 |
Postes actifs de David Elsley
| Sociétés | Poste | Début |
|---|---|---|
| CARDIOL THERAPEUTICS INC. | Founder | 19/01/2017 |
Anciens postes connus de David Elsley
| Sociétés | Poste | Fin |
|---|---|---|
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Founder | 23/10/2009 |
Formation de David Elsley
| University of Western Ontario | Masters Business Admin |
| Richard Ivey School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CARDIOL THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
